1478 studies found for:    "Melanoma"
Show Display Options
Rank Status Study
21 Active, not recruiting Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IV Melanoma
Intervention: Drug: vorinostat
22 Active, not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Mucosal Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: dinaciclib
23 Completed AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Intraocular Melanoma;   Iris Melanoma;   Lentigo Maligna Malignant Melanoma;   Recurrent Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
24 Not yet recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
25 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Solar Radiation-related Skin Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
26 Completed Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: bortezomib
27 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: pharmacological study;   Other: laboratory biomarker analysis
28 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: riluzole;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
29 Recruiting Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma
Conditions: Recurrent Melanoma;   Stage IA Melanoma;   Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: indocyanine green solution;   Drug: isosulfan blue;   Procedure: lymph node mapping;   Procedure: sentinel lymph node biopsy
30 Completed Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100 antigen;   Biological: tyrosinase peptide;   Biological: recombinant MAGE-3.1 antigen;   Biological: multi-epitope melanoma peptide vaccine;   Biological: incomplete Freund's adjuvant;   Drug: Montanide ISA 51 VG;   Drug: agatolimod sodium;   Other: laboratory biomarker analysis
31 Active, not recruiting Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Procedure: therapeutic conventional surgery;   Biological: bevacizumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
32 Recruiting Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Biological: therapeutic tumor infiltrating lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis
33 Completed Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Biological: cixutumumab;   Other: laboratory biomarker analysis
34 Active, not recruiting Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: tyrosinase peptide;   Biological: gp100 antigen;   Biological: MART-1 antigen;   Biological: incomplete Freund's adjuvant;   Drug: Montanide ISA 51 VG;   Biological: sargramostim;   Other: laboratory biomarker analysis
35 Recruiting Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: cabozantinib-s-malate;   Drug: temozolomide;   Drug: dacarbazine;   Other: laboratory biomarker analysis
36 Completed
Has Results
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IV Melanoma
Intervention: Drug: saracatinib
37 Recruiting Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: axitinib;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: 3'-deoxy-3'-[18F]fluorothymidine;   Procedure: positron emission tomography
38 Completed Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: gp100 antigen;   Drug: Montanide ISA 51 VG;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
39 Active, not recruiting VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: ziv-aflibercept;   Other: pharmacological study
40 Withdrawn Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
Conditions: GNA11 Mutation-positive Metastatic Melanoma;   GNAQ Mutation-positive Metastatic Melanoma;   Cancer;   Metastatic Uveal Melanoma
Intervention: Drug: GSK1120212

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years